Sometimes it’s difficult to separate the identity of a company from that of its CEO. For example, when we think of Amazon and Microsoft we naturally think of Jeff Bezos and Bill Gates. In the biopharmaceutical industry, it is hard to ponder Alkermes without thinking of Richard Pops.

Rob Wright discusses the difference between collaboration and teamwork, and what companies and leaders should be focusing on.

How we can fix biopharma’s broken and battered image was the topic of a panel of seven biopharma executives convened this year by Life Science Leader at the JPM Conference in San Francisco.

Deborah Waterhouse discusses her journey toward becoming CEO of ViiV Healthcare, an HIV joint venture between GSK, Pfizer and Shionogi, and her focus as a leader around innovation, building the “trust agenda” and company performance.

The biopharmaceutical industry has made significant contributions toward providing better outcomes for numerous ailments but fixing the industry’s sagging image will require more than just developing drugs for dreaded diseases.

The Conference Forum’s invitation only R&D Leadership Summit sheds light on areas of focus and concern for top biopharmaceutical industry executives.

During my 17 years in pharmaceutical sales, I spent most of my time calling on GP/FPs and OB/Gyns, and for a time I was responsible for selling the antidepressant Remeron/Remeron Soltab.

The story of how John Leonard found his “next adventure” in pharma as president and CEO of Intellia Therapeutics — and what he’s doing to capitalize on it.

The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.